French biotechnology company OSE Immunotherapeutics SA (Euronext Paris:OSE) on Monday announced positive results from the Phase 2 CoTikiS study of Lusvertikimab (OSE-127), an anti-IL7R monoclonal antibody, for the treatment of ulcerative colitis (UC).

Lusvertikimab met the primary endpoint, demonstrating significant improvement in the Modified Mayo Score at both doses tested. The drug also showed positive results on key secondary endpoints, including clinical and endoscopic remission.

The drug was well-tolerated with a favourable safety profile during both the induction and extension periods.

These results position Lusvertikimab as a potential first-in-class interleukin-7 antagonist for the treatment of autoimmune and inflammatory diseases.